Papillary renal cell carcinoma

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…

This early-stage trial is testing a new drug called ADCE-B05 in 180 people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to …

This early study tests a new treatment called SUV2208A, which uses a patient's own immune cells (T cells) that have been modified in a lab to recognize and attack cancer cells carrying a protein called CLDN18.2. The trial enrolls up to 18 adults with advanced solid tumors that ha…

This early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…

This phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combina…

This early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulves…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This study offers long-term treatment with nivolumab and other cancer therapies to 1,500 patients who previously benefited from Bristol-Myers Squibb trials. The main goal is to monitor safety and side effects over time. Participants must have had a good response in their earlier …

This study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.

This study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.

This early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This early-stage trial tests a daily oral drug called CGT6297 in 90 adults with advanced solid tumors that have a specific mutation in the PIK3CA gene. The study has two parts: first, finding a safe dose, and then looking for signs that the drug shrinks tumors. It focuses on peop…

This study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …

The DETERMINE trial is testing whether drugs already approved for some cancers can help people with rare cancers or common cancers that have rare genetic mutations. It will enroll 825 adults, teenagers, and children whose cancers have specific DNA changes. The goal is to find new…

This study explores how to best help cancer patients, survivors, and their caregivers quit tobacco. Participants can choose between group or one-on-one counseling sessions. The goal is to see if this program is practical and well-received, paving the way for better tobacco cessat…

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain breast, head and neck, or other cancers are being…

This early-stage study tests a new oral drug, DEG6498, in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Participants take the drug once daily and are closely monitore…

This study tests a new drug called nenocorilant combined with the immunotherapy nivolumab in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 50 participants w…

This early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …

This early-phase trial tests an antibiotic called novobiocin in people with advanced solid tumors that have specific DNA repair mutations (like BRCA). The drug blocks a protein cancer cells use to fix their damaged DNA, which may cause them to die. The study aims to find the safe…

This study is testing an experimental drug called LBL-024 in people with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 396 adults aged 18 to 80 are taking part. The drug is given…

This study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…

This early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors.…

This study tests a new drug called STK-012, which is designed to boost the immune system's ability to fight cancer. It is being tested alone or with standard treatments (pembrolizumab, pemetrexed, carboplatin) in people with advanced solid tumors, especially those with a type of …

This early-stage trial is testing an investigational drug called CX-801, alone or with the immunotherapy Keytruda, in 121 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will…

This study tests a new drug called HRS-4508 in combination with other cancer treatments (such as capecitabine, trastuzumab, and pertuzumab) for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose, check safety, and…

This early-phase trial tests a new oral drug called IPG7236 combined with the immunotherapy toripalimab in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding the safest dose of IPG7236, then expanding to see if the com…

This trial investigates whether ursodeoxycholic acid (UDCA), a bile acid medication, can protect kidney function in adults undergoing partial nephrectomy for kidney cancer. During surgery, blood flow to the kidney is temporarily stopped, which can cause injury. Participants take …

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This early-stage trial tests a new oral drug called ERAS-0015, alone or with other cancer drugs, in 600 adults with advanced solid tumors that have certain RAS mutations. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Researc…

This study is checking the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in 3500 people with various solid tumors or blood cancers. Participants are moving from earlier Merck studies into this one, continuing their treatment or follow-up. The goal…

This Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…

This early-stage trial tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer. The drug works by breaking down two proteins that help cancer cells grow. Researchers want to find the safest dose and see if it can shrink tumors…

This early-stage trial tests a new oral drug called SNV1521 in 400 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it can shrink tumors. Researchers will also test SNV1521 combined with other cancer drugs.

This early-stage trial tests a new drug called TQB3142 in 66 adults with advanced tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body and look f…

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…

This early-phase trial tests a new drug called BI-1206, given alongside the immunotherapy pembrolizumab, in adults with advanced solid tumors that have stopped responding to prior anti-PD-1/PD-L1 treatment. The study aims to find the safest dose and check for early signs of tumor…

This early-stage trial tests a new drug called ONC-841 in people with advanced solid tumors that have spread. The drug is an antibody designed to help the immune system attack cancer cells. The study will first find a safe dose, then test it alone and with standard treatments for…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This first-in-human study tests an experimental drug called CX-2051, alone or with Avastin, in 160 adults with advanced solid tumors that have worsened after standard treatment. The main goals are to check safety and find the right dose, while also looking for early signs of tumo…

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This study tests whether carefully managing body temperature during major cancer surgery can lower the risk of postoperative delirium (sudden confusion) and improve long-term survival in patients aged 65 and older. About 4,000 participants will be randomly assigned to either rout…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This early-stage trial is testing a new biologic drug called XB628, alone or with an oral drug called zanzalintinib, in people with advanced or metastatic solid tumors that have not responded to prior treatments. The study has two parts: first, finding a safe dose, and then check…

This trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…

This study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…

This early-stage trial is testing a new drug called lunresertib, alone or combined with two other experimental drugs (RP-3500 and Debio 0123), in people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for earl…

This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This early-stage trial tests an experimental drug called mocertatug rezetecan in 675 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The main goals are to check safety, find the ri…

This study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…

This early-phase trial tests an experimental drug called RSC-1255, given alone or with hydroxychloroquine, in people with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard options. The study has two parts: first, finding a safe dose, and …

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…

This early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…

This phase 2 trial is testing a drug called calderasib (MK-1084), given alone or with cetuximab, in 150 people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the cancer shrinks or disappears and to check for side effects. Participants mu…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This study tests a new drug called SW-682, taken as a tablet, for people with advanced solid tumors that have not responded to standard treatments. The trial focuses on tumors with changes in the Hippo pathway, including mesothelioma. In the first part, doctors will find the safe…

This study tests whether specially engineered immune cells (EIE) can safely fight cancer. Researchers take a patient's own immune cells, modify them to target tumor-related markers, and infuse them back. The trial involves 100 people with various cancers whose tumors show specifi…

This early-stage study tests a new drug called ZL-6201 in adults with sarcoma or certain solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. About 180 people will take part in this study.

This study tests a program called Comprehensive Connected Cancer Care (C4) for people newly diagnosed with cancer who also have social needs (like trouble paying for medicine or getting to appointments). The program uses patient navigators, a digital needs assessment, and better …

This phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…

This study tests a new drug called YL201 in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then testing that dose in more patients with specific cancer types. YL201 is given by IV every t…

This early-phase study tests a new drug called BG-C137, which delivers chemotherapy directly to cancer cells that have a specific marker (FGFR2b). The goal is to see if it is safe and can shrink tumors in people with advanced solid tumors who have run out of standard options. Abo…

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This early-stage study tests a new drug called AO-252 in people with advanced solid tumors, including those that have spread to the brain. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or stop them from growing. About 86 adults whos…

This early-stage study tests a new drug called CBA-1205 in people with advanced solid tumors (like liver cancer or melanoma) that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose. About 66 participants will receive the dru…

This phase II trial is testing whether three antibody-drug conjugates (ADCs) can shrink advanced or metastatic solid tumors that have high levels of specific proteins (Trop-2, nectin-4, or HER2). About 500 patients will first have their tumors tested for these markers, then recei…

This study tests whether combining two drugs, YL201 and ivonescimab, can safely shrink tumors in people with advanced solid cancers, including lung cancer. About 260 adults whose cancer has not responded to other treatments will receive the combination. The goal is to find the be…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This early-phase trial is testing a new drug called H1710 in 36 adults with advanced solid tumors who have no standard treatment options left. The main goal is to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also watch for any …

This early-phase study tests the safety and best dose of two drugs, ZEN003694 and abemaciclib, given together. It is for people with advanced breast cancer, NUT carcinoma, or other solid tumors that have spread or cannot be removed by surgery. The goal is to see if the combinatio…

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…

This phase 2 trial is testing whether a combination of three drugs—bevacizumab, erlotinib, and atezolizumab—can safely shrink or stabilize advanced kidney cancer in people with hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. The dr…

This phase 1 trial tests whether specially designed viruses (VSV-based oncolytic viruses) can safely treat advanced solid tumors that have not responded to standard treatments. The viruses are injected into the body to infect and destroy cancer cells. The study focuses on safety …

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This study tests whether a combination of two drugs (ZEN003694 and talazoparib) can shrink tumors in people with advanced solid cancers that have stopped responding to standard treatments. About 88 adults will take part. Researchers will also look at participants' genes to see if…

This early-phase trial is testing two experimental drugs, peposertib and tuvusertib, together in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest dose and to understand side effects. About 66 participants wi…

This early-stage trial is testing an experimental drug called MK-0472, alone or combined with the immunotherapy Keytruda or another experimental drug MK-1084, in people with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see how …

This study is testing a new type of radiation therapy called DaRT for people with malignant tumors. The main goal is to see how safe the treatment is and what side effects occur. Researchers will also check if the tumors shrink three months after treatment. About 100 adults with …

This phase 1 trial tests a new therapy called MSK-TCR5 for people with advanced solid tumors that have a specific genetic change (RAS G12D mutation) and a certain immune type (HLA-A*11:01). The therapy uses a patient's own T-cells, modified in a lab to better recognize and attack…

This early-phase trial is testing a new experimental drug called BNT3212, alone or with another drug (pumitamig), in 375 adults with advanced solid tumors who have no other treatment options. The main goals are to check safety, find the right dose, and get an early look at whethe…

This early-phase study is testing a new drug called OVV-01 in 18 people with advanced solid tumors that have not responded to standard treatments. The drug is given either through a vein or directly into a tumor. The main goal is to check safety and find the right dose, while als…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This study tests a new drug called IMP1734 in people with advanced solid tumors (breast, ovarian, or prostate cancer) that have not responded to prior treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 156 participants will ta…

This early-stage study tests a new drug called STP938 in 70 adults with advanced solid tumors that cannot be cured by current treatments. The main goal is to check safety and find the right dose. The study also looks at how the drug moves through the body and includes a special g…

This study tests a new biologic drug, CM518D1, in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors. About 434 par…

This early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…

This study tests whether adding a precise local treatment—like focused radiation or ablation—can help people whose cancer has a few new or growing spots while on standard therapy. Participants continue their usual medication while the resistant tumors are treated directly. The go…

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…

This study looks at the long-term safety and benefits of the drug pelabresib in people with blood cancers, solid tumors, or advanced cancers. It includes up to 50 adults who were in earlier pelabresib studies and are still benefiting from the drug. Some participants who received …

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This early-phase trial is testing whether a new drug called ZEN003694, when added to the chemotherapy capecitabine, is safe for people with advanced solid tumors that have spread or can't be removed by surgery. About 30 participants will receive the combination to find the best d…

This study tests whether specially grown donor immune cells (called cytotoxic T lymphocytes) can safely and effectively control BK and JC virus infections in people with weakened immune systems, such as those with cancer, HIV, or organ transplants. About 100 participants will rec…

This study tests a new drug called PM54 combined with the immunotherapy pembrolizumab in adults with advanced cancers that have not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing. About 119 par…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This early-stage trial tests a new drug called AN8025 in about 91 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants receive the drug in 3-week cycles and are closely moni…

This early-stage study is testing a new drug called MG2512 in about 116 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also w…

This early-stage trial tests a radioactive drug that seeks out and delivers radiation directly to cancer cells with a specific protein (somatostatin receptor). It is for adults with advanced lung, kidney, head and neck, digestive tract, or adrenal gland tumors that cannot be remo…

This phase 2 trial tests a new radiation technique called SBRT-LATTICE-PATHY for people with large tumors (at least 7 cm or 340 cm³) that cannot be treated with standard methods. The approach delivers a high dose of radiation only to low-oxygen areas inside the tumor, aiming to i…

This study gives people with cancer continued access to an experimental Roche treatment they were already receiving in a previous trial. It is for patients who still need the drug and cannot get it locally. The goal is to keep providing the treatment and monitor any side effects.

This study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…

This phase 2 trial tests the drug avapritinib in 50 adults with advanced solid tumors that have mutations in the CKIT or PDGFRA genes. The drug blocks enzymes that help cancer cells grow. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also…

This early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…

This early-stage study tests a new drug called ADCX-020 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody drug conjugate designed to deliver cancer-killing agents directly to tumor cells. The study will first find th…

This study tests a new treatment made from specially engineered immune cells (T cells) donated by healthy people. The cells are designed to better recognize and kill cancer cells while lasting longer in the body. The trial includes 24 adults with blood cancers or solid tumors tha…

This study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, t…

This early-stage study tests a chemotherapy drug (JNJ-1761981) that is injected directly into tumors in people with solid cancers that have not responded to standard treatments. The goal is to find a safe and effective dose, and to see if adding an immunotherapy (cetrelimab) help…

This study tests a new drug called IAH0968, given alone or with chemotherapy (CAPEOX), in people with advanced HER2-positive stomach cancer or other solid tumors. The goal is to see if the combination is safe and helps slow cancer growth better than standard treatment. About 574 …

This study tests a new drug called STX-478 in people with advanced solid tumors that have a specific genetic change (PI3Kα mutation). The trial has two phases: first, it tests STX-478 alone to find safe doses; then, it combines STX-478 with other cancer drugs like fulvestrant or …

This study tests a new cancer drug, repotrectinib, combined with standard chemotherapy in children and young adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if the combination can shrink tumors. Researchers will also study how the b…

This early-phase study tests an experimental drug called JNJ-89862175 in people with advanced solid tumors (lung, kidney, ovarian, or uterine cancers that have spread). The drug is designed to deliver a toxic payload directly to cancer cells. The main goals are to find a safe dos…

This study tests a new drug called OSE-279 that helps the immune system fight cancer. It is for people with advanced solid tumors or lymphomas that have not responded to other treatments. The trial has three parts: finding the right dose, checking safety, and measuring how well t…

This early-phase trial is testing an experimental oral drug called ABBV-CLS-484, either alone or combined with other cancer treatments, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to find safe and tolerable doses and to se…

This early-phase study tests a virus (JNJ-87704916) that is injected directly into tumors to kill cancer cells. It is being tested alone and with another drug (cetrelimab) in people with advanced solid tumors who have run out of standard treatments. The main goals are to check sa…

This early-stage trial tests an experimental drug called TEV-56278, alone or with the immunotherapy pembrolizumab, in 240 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug…

This study is testing a non-invasive radiation treatment called SABR for people with kidney tumors who are not good candidates for surgery. The goal is to control the tumor while keeping the kidneys working well. About 90 participants will receive high-dose radiation and be follo…

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …

This early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…

This study tests a new drug called AZD5335, alone or with other cancer medicines, in people with advanced solid tumors like ovarian, lung, and endometrial cancers. The goal is to see if the drug is safe, tolerable, and shows signs of shrinking tumors. About 506 participants will …

This early-stage trial is testing an experimental drug called HS-20108 in 502 people with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe dose and check for side effects. Researchers will also look for any signs that the drug might shr…

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This study tests a new drug called UI-102, which is a tiny nanoparticle designed to activate the immune system to fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments. The trial will enroll 140 participants to first find the saf…

This early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…

This early-phase trial tests an experimental oral drug called ST-01156 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dose and check for side e…

This early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …

This study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…

This study is for children whose solid tumors have returned or not responded to standard therapy. It combines an immunotherapy drug (atezolizumab) with three chemotherapy drugs to see if the mix is safe and can shrink tumors. About 23 children will take part, and the main goals a…

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This early-phase trial tests a new biologic drug called SBO-154 in 177 people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrink…

This early-phase study tests a new drug called RC220 given with the chemotherapy doxorubicin in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if RC220 can protect the heart from doxorubicin's sid…

This study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …

This study tests an experimental drug called INV-6452 in adults with advanced breast cancer (HR+/HER2-) or other solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 201 participants wil…

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …

This early-phase study tests a new drug called CT3001 in people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose of CT3001 alone, then testing it combined wit…

This study tests an experimental drug, REGN7508, to see if it works better than the standard blood thinner apixaban for treating and preventing blood clots in people with cancer. The trial will include about 1,600 participants with or without cancer who have deep vein thrombosis …

The TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…

This early-phase study tests a new experimental drug (BI 3819026) alone and with another drug (ezabenlimab) in adults with advanced solid cancers that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. About 60 particip…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This early-stage trial tests the safety of a new drug called ERX-315 in 36 adults with advanced solid tumors (like breast, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. Participants receive the drug intravenously twice a week at increasing do…

This study looks at how the cancer drug ASTX727 (decitabine and cedazuridine) works in people with moderate or severe liver problems. About 27 adults with certain blood cancers or solid tumors will take the drug for up to 8 weeks. The goal is to understand how the liver affects t…

This early-stage study looks at how the body handles the cancer drug ASTX727 (decitabine and cedazuridine) in people with severe kidney problems compared to those with normal kidneys. It includes 18 adults with acute myeloid leukemia, myelodysplastic syndromes, or solid tumors. T…

This study tests a new drug called BMS-986523, alone or with other cancer drugs, in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change (KRAS mutation). The goal is to see if it is safe and works. About 252 adults wi…

This early-stage trial tests whether adding a chemotherapy drug (5-Azacitidine) to standard immunotherapy can help patients whose solid tumors have stopped responding to PD-1/PD-L1 inhibitors. About 35 adults with advanced or metastatic cancers will receive the combination to fin…

This early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…

This early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body …

This early-stage trial tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The study will check for safety, side effects, and whether the drug can s…

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This early-stage trial tests a new drug called EVM14, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug helps control the cancer. A…

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

This early-phase study tests a new drug called GSK5533524, alone or with other cancer treatments, in adults with advanced solid tumors that have stopped responding to standard therapies. The main goals are to find a safe dose and see if the drug can shrink tumors or slow cancer g…

This early-stage trial is testing a new drug that delivers a tiny amount of radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study will check if the drug is…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This study tests a new drug, ALK201, for the first time in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 202 adults aged 18 to 75 will take part. The study is currently r…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This early-stage trial is testing a drug called orellanine, derived from a mushroom, in 75 people with advanced kidney cancer who are also on dialysis. The drug is given intravenously to see if it is safe and can shrink tumors. All participants have end-stage kidney disease and h…

This study tests a new drug called mocertatug rezetecan (Mo-Rez) combined with other cancer medicines for people with advanced solid tumors that have stopped responding to standard treatments. About 305 adults will join to see if the combination is safe, tolerable, and effective.…

This early-stage trial is testing a new drug called Risvutatug rezetecan (Ris-Rez) in people with advanced solid tumors that have spread or cannot be removed. The study will give Ris-Rez alone or combined with other cancer drugs like chemotherapy or immunotherapy. Researchers wan…

This study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …

This early-stage trial is testing a new drug, QLS5212, in 100 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to find …

This early-phase study is testing a new treatment called KXV01 for people with advanced solid tumors, including sarcomas, who have no other options. The therapy uses a patient's own immune cells, modified with a virus to recognize and attack their specific tumor. The main goal is…

This study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…

This early-stage study tests a new injection called SHR-4506 in 102 adults with advanced malignant tumors who have run out of standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow the disease. Participants must …

This study tests a new drug, SKB103, in people with advanced solid tumors who have run out of standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 277 adults aged 18 to 75 will take part.

This early-phase trial tests AMT-676, a drug designed to seek out and destroy cancer cells that carry a protein called CDH17. It is given intravenously to 24 adults with advanced solid tumors (such as colorectal, gastric, or pancreatic cancer) that have not responded to prior tre…

This early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…

This early-phase trial is testing whether combining two targeted drugs, pemigatinib and afatinib, is safe and can shrink tumors in people with advanced solid cancers that have specific FGTR gene changes. The study includes up to 70 participants whose cancers have spread or cannot…

This study is the first time the drug BNT3214 is being tested in people. It aims to find a safe and effective dose for adults with advanced solid tumors. The trial has three parts: first, finding the best dose; then, testing it in different cancer types. About 533 participants wi…

This early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells (T-cells) that are genetically modified in a lab to recognize and attack a protein called PRAME found on cancer cel…

This early-phase trial tests a new drug called SXRN, made from DNA, in 28 people with advanced solid tumors who have run out of standard options. The main goals are to check safety and find the right dose, while also seeing if it helps with appetite and physical function. The stu…

This early-stage trial is testing a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The drug works by attaching to two proteins (EGFR and c-Met) found on some cancer cells and delivering two anti-cancer agents directl…

This study tests a mix of five oral drugs (hydroxychloroquine, metformin, sirolimus, dasatinib, and nelfinavir) in people with advanced solid tumors or prostate cancer that has come back. The goal is to find the safest dose and see if the combination can stop the cancer from grow…

This early-phase study tests a new drug called TAK-243 in adults with advanced solid tumors or lymphoma that has not responded to standard treatments. The main goal is to find the safest dose and check for side effects. TAK-243 works by blocking a protein that cancer cells need t…

This early-phase trial is testing a new drug called IUAb190708, an antibody designed to attack cancer cells by targeting a protein called PD-L1. The study involves 90 adults with advanced or recurrent solid tumors who have run out of standard treatment options. The main goal is t…

This early-stage study tests a new drug called SIGX1094R in about 102 adults with advanced solid tumors who have no standard treatment left. The main goals are to check the drug's safety, find the right dose, and see how it affects tumors. Researchers will also look at how food c…

This early-phase study is testing a new drug called PEEL-224 in 65 people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug can shrink tu…

This study is testing an experimental oral drug called RMC-6236 in adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have specific RAS mutations. The main goals are to find safe doses and understand side effects. About 754 participants will take…

This early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The study will first find a safe dose of VAX014 alone, then te…

This early-phase trial tests a new treatment made from specially engineered cord blood cells (TROP2-CAR-NK cells) in adults with advanced solid tumors that have not responded to standard therapies. The main goal is to find a safe dose and monitor side effects. Up to 54 participan…

This early-stage trial tests whether injecting specially reprogrammed immune cell particles (exosomes) directly into tumors is safe for people with advanced solid tumors who have run out of standard options. Nine adults aged 18-65 will receive four injections over eight weeks. Th…

This study tests a new drug called SHR-9839, given with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination is safe and can shrink tumors. About 156 adults aged 18-75 with certain cancer…

This early-phase trial is testing a new drug called PT0511, given alone or with cetuximab, in adults with advanced solid tumors that have a KRAS mutation or amplification. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 195 par…

This early-phase trial is testing a new drug, SKB500, in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also look for ear…

This study tests a drug called romiplostim N01 in children, adolescents, and young adults (ages 6-24) with cancer who develop low platelet counts from chemotherapy. The drug is given as a weekly shot to help the body produce more platelets. The goal is to see if it can safely and…

This study tests a new drug, ODM-212, in about 315 adults with advanced solid tumours that cannot be cured with current treatments. The trial has two parts: first finding a safe dose, then testing that dose in more people. The main goal is to check for side effects and see how th…

This early-stage trial tests a new drug called SKB518 in 150 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants receive the drug every …

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This early-phase trial is testing an experimental drug called SKB445 in 126 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and get an early look at whether the drug can shrink tumors. Part…

This study tests whether a single injection of Telpegfilgrastim works better than daily Filgrastim shots to prevent fever and low white blood cells in children and young adults (ages 6-24) with solid tumors receiving strong chemotherapy. About 132 participants will receive either…

This early-phase study tests the safety and best dose of SKB315, a drug designed to attack cancer cells with a specific protein called Claudin18.2. About 246 adults with advanced solid tumors that haven't responded to standard treatments will receive the drug. The goal is to see …

This study tests a telehealth program to help cancer survivors quit smoking, lose weight, and get more active. About 1500 participants will either get coaching sessions or just information. The goal is to see which approach works better for improving long-term health.

This early-phase study tests a new drug called VVD-130037 in people with advanced solid tumors that have stopped responding to standard treatments. The drug aims to activate a protein (KEAP1) to fight cancer. Researchers will check safety, side effects, and whether the drug works…

This study tests a new drug called SKB105 in 256 adults with advanced solid tumors that have not responded to standard treatments. SKB105 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial will first find the safest dose, then check…

This early-phase trial tests a new drug called SKB571 in 138 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to check safety and find the right dose, while also looking for signs that the drug shrinks tumors. Participants recei…

This study tests an experimental daily pill called REC-1245 in people with advanced solid tumors or lymphomas that have not responded to or are not eligible for standard therapies. The main goals are to find a safe dose and check if the drug can shrink tumors. About 170 adults wi…

This early-phase trial is testing a new daily pill called NDI-219216 for people with advanced solid tumors that have not responded to standard treatments. The study will first check safety and side effects, then look at whether the drug can shrink tumors. About 134 participants w…

This early-phase trial is testing a modified salmonella bacteria, called SGN1, in 70 people with advanced solid tumors that have not responded to standard treatments. The bacteria are designed to grow inside tumors and release an enzyme that breaks down methionine, an amino acid …

This study tests a new drug called DT-7012, alone or with another cancer drug (an immune checkpoint inhibitor), in 125 adults with advanced solid tumors that have not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors. It is an earl…

This study tests whether the antiviral drug letermovir can prevent cytomegalovirus (CMV) infection in children and teens who have had a stem cell transplant. About 105 participants aged 2 to 17 will receive letermovir and be monitored for 14 weeks. The goal is to see if the drug …

This study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…

This study tests a modified herpesvirus (T3011) combined with standard immunotherapy drugs (PD-1/PD-L1 inhibitors) in people with advanced solid tumors that have not responded to other treatments. The goal is to see if the combination is safe and can shrink tumors. About 68 parti…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This expanded access program offers balstilimab, alone or with zalifrelimab, to cancer patients who previously received these drugs in a clinical trial and saw benefit. The goal is to allow continued treatment for those who wish to stay on therapy. Only patients who completed the…

This study tests whether a special CT scan with contrast dye can give clearer images of tumors during radiation therapy. Twenty adults with advanced cancer will receive the extra scan alongside their standard treatment. The goal is to see if this approach is feasible and improves…

This early-stage study tests a new injection called [18F]LY4214835 to see if it is safe and how it spreads in the body. It includes healthy volunteers and people with cancer. The goal is to improve how doctors see tumors using imaging scans.

This early-phase study tests a new radioactive tracer called FAP-2286 to see how well it can detect cancer that has spread in adults with solid tumors. About 191 participants will receive the tracer and then have a PET scan. The goal is to measure safety and how clearly the trace…

This study is testing a special type of PET/CT scan that looks for a protein called PD-L1 on cancer cells. The goal is to see if this scan can find tumors and their spread more accurately than standard imaging. About 500 adults with suspected or known PD-L1-related cancers will r…

This study is testing a special MRI scan that uses a unique contrast agent to see how aggressive advanced solid tumors are and how they respond to treatment. About 65 people with advanced solid tumors will get the scan before and during their standard cancer therapy. The goal is …

This study is testing a new radioactive tracer called 18F-FGln, which targets glutamine—a nutrient that cancer cells need to grow. Researchers want to see if PET/CT scans using this tracer can more accurately detect and stage various cancers, especially those that are hard to see…

This early-stage study tests a new imaging agent called 18F-4FN for PET scans to safely detect inflammation in the body. It involves 55 adults with cancer who are on immunotherapy or have suspected inflammation. The goal is to see if this agent can highlight areas of inflammation…

This study is testing a new blood test that looks for DNA from cancer cells. The goal is to see if an artificial intelligence program can accurately detect many different types of cancer at an early stage. The study will include 6,000 adults, some with cancer and some healthy vol…

This study is testing a new radioactive imaging agent called 68Ga-DOTA-EphA2 to help see certain proteins on cancer cells during PET/CT scans. The goal is to improve how doctors detect and monitor malignant tumors. About 30 adults with suspected or confirmed cancer will receive t…

This study tests a new radioactive tracer called 68Ga-NK224 that lights up PD-L1, a protein on cancer cells, during a PET/CT scan. Researchers want to see if the scan can accurately measure PD-L1 levels compared to standard tissue biopsy. One hundred adults with various cancers w…

This study is testing a new blood test that looks for DNA and protein signals from cancer cells. The goal is to find multiple types of cancer early, before they cause symptoms. Researchers will compare blood samples from 20,000 people with and without cancer to see if the test wo…

This early-stage study tests a single dose of a new radioactive tracer called [68Ga]Ga-R54, which attaches to a protein (CXCR4) found on some cancer cells. Ten adults with advanced solid tumors or multiple myeloma will receive the tracer and then have a PET/CT scan to see where i…

This study tests whether a dexamethasone mouthwash can prevent moderate to severe mouth sores caused by chemotherapy in adults with cancer. Participants use the mouthwash four times daily during chemo for up to 8 weeks. Researchers compare their outcomes to a historical group to …

This study tests a special cooling and compression sleeve (Paxman Limb Cryocompression System) worn during chemotherapy to prevent nerve damage, a common side effect. About 200 cancer patients receiving weekly paclitaxel will use the device for up to 4 hours per session. Research…

This study tests whether taking a daily statin (rosuvastatin) for one year can safely prevent life-threatening blood clots in people with cancer. Current clot-preventing drugs raise bleeding risks, so a safer option is needed. The trial will enroll 4,000 adults with newly diagnos…

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

This study tests a virtual group program designed to help people with advanced cancer build resilience and manage stress, anxiety, and fatigue. Participants attend seven weekly online sessions that teach techniques like mindfulness, gratitude, and reframing difficult experiences.…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study adapts a program called CONVO for Spanish-speaking Latinx adults with solid tumors. In the program, nurses talk with patients about their personal values during routine cancer care. The goal is to make care more respectful and supportive. About 234 adults will take par…

This pilot study explores how four different meditation practices—breathing only, focused attention only, mindfulness only, and a combination of all three—affect relaxation in cancer survivors. Many cancer patients experience stress and anxiety, and meditation may help reduce dis…

This study tests whether a smartphone app that teaches mindfulness can help reduce stress in people who have finished cancer treatment. About 345 cancer survivors will be randomly assigned to use the app right away or wait three months. The goal is to see if the app makes a real …

This study tests whether using virtual reality (VR) can improve symptoms like pain, anxiety, and fatigue in patients receiving a bone marrow transplant. About 28 adults will be randomly assigned to either VR sessions or standard care during their hospital stay. The goal is to see…

This study tests a mobile app called PACT that helps people with advanced cancer talk about and plan the care they would want if they couldn't speak for themselves. The app involves patients and their loved ones in these discussions. Researchers want to see if the app is easy to …

This study compares opioid-free anesthesia to standard opioid-based anesthesia in 600 adults undergoing urological abdominal surgery. The goal is to see if avoiding opioids during surgery reduces the need for painkillers afterward and lowers side effects like nausea. Patients wil…

This study tests whether eating only within an 8-hour window (time-restricted eating) can improve how well cancer treatments work and reduce side effects. It involves 100 Alaska Native and American Indian patients with breast or rectal cancer. Participants will follow the eating …

This study tests whether regular phone check-ins and counseling can help people on oral cancer drugs feel better and avoid hospital visits. 600 patients will be assigned to symptom monitoring alone, or monitoring plus a self-help handbook and phone counseling for anxiety or sadne…

This study tests an experimental drug called LY3537021 to see if it can better control nausea and vomiting caused by chemotherapy in adults with cancer. About 204 participants will receive either the drug or a placebo, and researchers will track who has no vomiting and does not n…

This pilot study tests whether a virtual mindfulness-based stress reduction (MBSR) program can improve mental health in cancer patients living in underserved or rural parts of Minnesota. About 45 participants will take the online course and report changes in stress, anxiety, and …

This study tests whether a diet low in added sugar, high in fiber, and rich in omega-3s (called LASO-3) can help reduce nerve pain, numbness, and tingling caused by chemotherapy. Fifty cancer survivors who finished chemo at least three months ago will receive virtual nutrition co…

This study tests whether a type of talk therapy called behavioral activation (BA) can help treat depression in older adults who have survived cancer. Participants will receive BA or supportive psychotherapy remotely via video or phone over 10 weeks. The goal is to see if BA reduc…

This study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…

This study looks at whether using a weighted blanket during intravenous cancer treatment can help lower anxiety, stress, and depression, and improve comfort. About 152 adults with solid cancers who are starting their first IV therapy will be randomly assigned to receive either a …

This study tests a support program for Chinese cancer patients and survivors that includes education sessions, counseling, and peer support. The program is delivered by phone or video call. Researchers want to see if the program is practical and whether it improves quality of lif…

This study tests a drug called Pedmark (sodium thiosulfate) to see if it can prevent hearing loss in adults receiving cisplatin chemotherapy for cancers like testicular, head and neck, or thoracic cancer. About 25 adults will take Pedmark alongside their chemo. The drug is alread…

This trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…

This study aims to train psychotherapists to deliver personalized, evidence-based therapies to cancer patients and their caregivers who are experiencing high levels of distress. Therapists will choose from treatments like cognitive behavioral therapy and mindfulness-based stress …

This study is testing a new way to manage care for 33 cancer patients who take oral chemotherapy at home. Instead of going to the hospital every month just to pick up medicine, a nurse will visit them at home twice in six months. An advanced practice nurse will coordinate everyth…

This study tests whether a mobile app called Tools for Coping with Cancer can help people with a history of cancer reduce distress and improve mood and quality of life. About 50 adults who have had cancer will use the app at home for 8 weeks and fill out questionnaires about thei…

This study compares two ways to treat depression in cancer survivors: a mobile app called Moodivate that tracks activities and mood, and 8 sessions of telehealth therapy with a mental health provider. About 45 adults who have had cancer and currently feel depressed will take part…

This study compares two types of ultrasound-guided nerve blocks for pain control after open kidney removal surgery. Ninety adults will receive either a rhomboid intercostal sub-serratus plane block or an external oblique intercostal block. Researchers will measure how long it tak…

This study tests a program called ICCAN that gives cancer patients extra help with social and economic needs, like finding resources and monthly check-ins. Researchers want to see if this support helps patients complete their cancer treatment and improves their quality of life, c…

This study tests special gloves and boots that gently squeeze the hands and feet during chemotherapy. The pressure may reduce how much chemo reaches the nerves, possibly preventing pain and numbness. About 142 adults with cancer will try the devices to see if they help avoid nerv…

This study tests a program to help cancer patients transition from hospital to home. It includes a meeting with a nurse before leaving, an app to report symptoms, and a follow-up phone call. The goal is to see if this approach is feasible and improves patient satisfaction and qua…

This study tests a program called ROCKS that helps people with advanced cancer and their family caregivers build optimism, communication skills, and knowledge to discuss advance care planning. 152 patient-caregiver pairs will be randomly assigned to the ROCKS program or usual car…

This phase 3 trial tests whether a precise, high-dose radiation technique (SBRT) provides better pain relief than standard radiation for cancer patients with painful bone metastases not in the spine. About 230 adults with solid tumors and moderate to severe pain will be randomly …

This study is testing a support program for teens and young adults (ages 16-30) who have just been diagnosed with cancer. The program includes a meeting with a special team and a structured course called PRISM that teaches skills like stress management and goal setting. About 130…

This early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…

This study tests whether group sessions that teach stress management skills can lower distress in people with cancer. About 400 adults with cancer who have moderate distress will take part. The program helps patients recognize and reduce stress in their daily lives.

This study tests whether virtual reality (VR) can help children and young adults with cancer be more physically active while in the hospital. 40 participants aged 10-25 will try both VR-assisted physical therapy and traditional physical therapy to see which one gets them moving m…

This study tests a web-based program called OMGYES.com to see if it helps young adult female cancer survivors who have sexual problems. About 30 people will take part, using online modules at home and visiting the clinic every 5 weeks for questionnaires. The goal is to see if the…

This study is testing a program called FOCUS ON US, designed to help sexual and gender minority (LGBTQ+) cancer patients and their caregivers. The program includes five sessions covering topics like family involvement, coping skills, and symptom management. Researchers want to se…

This study tests whether expressive writing—reading and writing about positive experiences—can help cancer survivors manage stress. About 414 survivors will participate from home using a computer or smartphone. The goal is to see if this simple activity can lower stress and impro…

Chemotherapy often causes nausea and vomiting, which is especially hard for children. This study tests a new IV drug called NEPA (fosnetupitant/palonosetron) to prevent these side effects in kids with cancer. The trial has two parts: first, an open-label phase to find the right d…

This study tests whether a single injection of RE104 can reduce symptoms of depression or mixed depression and anxiety in people with adjustment disorder caused by a serious medical illness like cancer, ALS, multiple sclerosis, Parkinson's disease, or idiopathic pulmonary fibrosi…

This study tests two types of spiritual care for people with advanced cancer. Researchers want to see if these programs improve spiritual well-being and reduce hospital visits. About 288 patients from religious communities will take part.

This study looks at whether two simple relaxation methods—progressive muscle relaxation and deep breathing exercises—can reduce shortness of breath and severe tiredness in people with advanced cancer receiving palliative care. About 90 participants will be assigned to one of the …

This study tests an online program called My Wellbeing Guide for cancer patients who feel depressed or anxious. The program uses videos, activities, and written tips based on cognitive behavioral therapy over 7 weeks. About 6,500 participants will be randomly assigned to the prog…

This study tests whether taking a short chain fatty acid supplement can reduce gut-related side effects in people receiving radiation therapy for cancers in the abdomen or pelvis. About 122 adults will be randomly assigned to receive either the supplement or a placebo. The goal i…

This study tests a physical activity program designed for cancer survivors and their caregivers. About 164 adults who have finished cancer treatment (except hormone therapy or maintenance chemo) will take part. The goal is to see if the program improves physical function and redu…

This study tests whether virtual group therapy based on Acceptance and Commitment Therapy (ACT) and compassion practices can improve psychological well-being in cancer patients. Researchers at Mayo Clinic will enroll 200 adults with cancer who are experiencing stress. Participant…

This study tests whether a telephone coaching program called Talking About Cancer (TAC) helps people with advanced cancer and their support person engage in advance care planning, such as having end-of-life conversations and completing advance directives. About 80 patients and th…

This study tests whether acupressure, a non-invasive technique using finger pressure on specific body points, can reduce anxiety in cancer patients receiving chemotherapy. Researchers will compare real acupressure to a sham (placebo) version in 78 adults with cancer. The goal is …

This study tests a program called TRACT that helps cancer patients with travel to their radiation therapy appointments. Many patients miss or delay treatment due to transportation issues. The program provides navigation support and resources. Researchers will see if it is practic…

This study is testing a short group therapy program based on Dialectical Behavior Therapy (DBT) to help cancer patients reduce or stop smoking. The program focuses on building skills in emotion regulation, distress tolerance, and mindfulness. The trial will enroll 16 participants…

This study tests whether a special low-calorie, plant-based diet that mimics fasting can reduce common side effects like rash, diarrhea, and fatigue in cancer patients receiving immunotherapy. Ten adults with advanced cancer will follow the diet and report their symptoms. The goa…

This study compares music therapy and cognitive behavioral therapy (CBT) for reducing anxiety in people who have had cancer. 368 cancer survivors with anxiety will receive seven weekly virtual sessions of either music therapy or CBT. Researchers will track anxiety levels over 26 …

This study tests a communication coaching program for adolescent and young adult cancer survivors (ages 18-35) who have finished treatment at least a year ago. Participants complete online sessions and AI coaching to improve how they talk with peers. The goal is to see if the pro…

This study tests a computer program called C-SCAT that helps adolescents and young adults with cancer track and manage their symptoms. Participants use the tool to rate symptoms, find patterns, and plan how to cope. The goal is to see if using C-SCAT boosts their confidence and a…

This study tests whether a traditional herbal formula called MZRW can help cancer survivors who suffer from constipation. Researchers will give 70 participants either MZRW or a placebo for two weeks and track bowel movements and gut bacteria changes. The goal is to see if MZRW is…

This study looks at whether teaching cancer patients about taste changes caused by chemotherapy and giving them self-management tools can help reduce those symptoms and maintain healthy eating. About 400 adults starting chemotherapy will be split into two groups: one gets standar…

This study tests whether a combination of diosmin and hesperidin, natural compounds found in citrus fruits, can protect the kidneys of cancer patients receiving platinum-based chemotherapy. One hundred adults with confirmed cancer will take the supplement alongside their chemo to…

This study looks at whether a culturally tailored Latin dance program can help Hispanic cancer survivors sleep better. Researchers will enroll 40 adults who have finished their main cancer treatment but still have trouble sleeping. Participants will either take dance classes or c…

This study looks at whether a digital art activity can help cancer patients better express their distress, symptoms, and experiences. Researchers will enroll 60 adult cancer patients who are currently receiving treatment. Participants will use a digital tablet to create art and t…

This study tests a 9-week mindfulness program (MBRP-SA) designed to help cancer survivors quit smoking and reduce heavy drinking. Six hundred participants in Florida will either get the mindfulness program plus nicotine patches or standard quitline support. The goal is to see if …

This study is testing an online educational program called On-Trac to help adult cancer survivors cope with anxiety. The program teaches practical strategies based on well-known therapies like CBT and ACT. Researchers will measure changes in anxiety levels and emotional well-bein…

This study tests whether a walking program and cognitive rehabilitation exercises can improve memory and thinking in people aged 65 and older who have finished cancer treatment. Forty participants will be randomly assigned to one of four groups: exercise only, cognitive training …

This study tests whether an artificial intelligence (AI) app can improve quality of life, anxiety, and depression in people with cancer who are already receiving psychotherapy. About 60 participants will be randomly assigned to either get the AI app alongside their usual therapy …

This study is creating and testing a nurse-led program for women who experience early menopause after cancer. The program includes personalized education, decision support, and skills to manage menopause symptoms. About 117 women who have completed cancer treatment will take part…

This study looks at whether having access to a specialized palliative care clinic helps cancer patients feel more secure and reduces unnecessary hospital visits. Researchers will compare patients who use the clinic with those who do not, and also ask family members about their ex…

This pilot study tests whether brodalumab, a drug used for autoimmune conditions like psoriasis, can safely reduce immune-related side effects caused by cancer immunotherapy. About 11 adults with advanced solid tumors who developed these side effects will receive brodalumab injec…

This study tests a single, high-dose radiation treatment called spatially fractionated radiation (SFR) for people with large tumors (over 8 cm) or tumors that resist standard radiation. The goal is to see if one session can relieve symptoms as well as multiple sessions, with fewe…

This study tests whether Reiki, a gentle hands-on relaxation therapy, can help adults with cancer who feel very tired from immunotherapy. Twelve participants will either receive six weekly Reiki sessions right away or after a waiting period. Researchers will measure changes in fa…

This study is testing a weight loss program that uses a smartphone app and a coach to help teens and young adults who are overweight after a stem cell transplant. The goal is to see if the program can help them lose weight and build healthy eating habits. About 20 people who are …

This study tests four different approaches—behavioral therapy, physical therapy, medication changes, and buprenorphine rotation—to help cancer survivors reduce their opioid use while keeping pain under control. It involves 294 veterans who have finished cancer treatment but still…

This study tests whether a 12-week personalized exercise program, done at home with a trainer guiding via video, can improve quality of life and reduce common side effects like fatigue, anxiety, and nerve pain in cancer survivors. About 350 adults who finished cancer treatment wi…

This study looks at whether asking people with advanced cancer about their financial struggles each month can help reduce their worry and improve their quality of life. About 1,000 adults receiving treatment for advanced or metastatic cancer will be randomly assigned to either mo…

This study tests if listening to a guided meditation before cancer surgery can lower anxiety more than sitting in silence. About 300 adults scheduled for cancer surgery will take part. Researchers will measure anxiety levels and also track pain medicine use after surgery to see i…

This early-stage study tests whether L-theanine, a natural substance found in green tea, can help cancer patients who have finished treatment feel more relaxed and improve their mood. Researchers will enroll 50 adults to find the best dose and see if it's practical to use. The go…

This pilot study at St. Jude Children's Research Hospital explores whether a guided writing exercise can help teenagers and young adults (ages 15-25) cope with their cancer experience. Participants will write about their experiences and then share their thoughts in an interview. …

This study tests whether a simple card game, the Go Wish Game, can help people with advanced blood cancers or solid tumors discuss their end-of-life priorities with doctors. About 75 patients will use the cards to sort what matters most to them, then complete an advance care plan…

This study tests whether a supervised 12-week exercise and nutrition program in a community setting is practical and helpful for cancer survivors. About 150 participants, including survivors and their caregivers, will wear activity trackers, attend exercise sessions, and receive …

This study explores whether a simple writing exercise can help people living with or after cancer feel better emotionally. Participants will write about their cancer experience in four sessions, either with a compassionate prompt or a standard one. Researchers will measure change…

This study looks at whether a one-year, home-based exercise program can help people aged 60 and older who are undergoing cancer treatment. Participants will be split into two groups: one doing guided exercises at home, and the other receiving usual care. Researchers will measure …

This study tests whether a token-based exercise program called TEAM Me can help children and young adults (ages 6-29) with cancer stay active while undergoing a stem cell transplant. Participants earn stickers for walking and other activities, which they can trade for rewards. Th…

This study tests whether MDMA (the drug in ecstasy) combined with talk therapy can help cancer patients and their partners who are struggling with adjustment disorder—a condition where they have trouble coping with the cancer diagnosis. Twenty participants (10 patient-partner pai…

This pilot study tests a behavioral program called Mindset Moments for young adults (ages 19-25) who have finished cancer treatment. The program includes weekly online group sessions and daily app activities focused on coping skills, mindfulness, and peer support. Researchers wan…

This study tests whether taking alpha-lipoic acid, a natural antioxidant, can prevent kidney damage in cancer patients receiving cisplatin chemotherapy. About 50 adults with solid tumors will receive either alpha-lipoic acid or a placebo alongside their chemo. Researchers will mo…

This study tests whether a digital chatbot can help more adolescents and young adults (AYA) with cancer get genetic counseling and testing compared to standard remote services. About 535 participants aged 18-39 will use either a chatbot or standard telehealth. The goal is to see …

This study collects blood, tissue, and medical information from 240 cancer patients who have had serious side effects from immunotherapy. The goal is to store these samples in a national biorepository for future research. By studying these samples, scientists hope to better predi…

This study follows about 700 cancer patients who have already received radiation therapy to understand the long-term side effects and how their disease progresses over time. No new treatments are given—researchers simply collect data from routine follow-up visits. The goal is to …

This study looks at how to better support adults aged 65 and older during chemotherapy. Researchers will use a frailty score to create personalized care plans and track how well participants handle treatment. The goal is to see if this approach improves resilience and reduces hos…

This study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…

This study will test a new robotic surgery platform called RonovoTM in 40 adults with cancer who need elective surgery. The robot helps surgeons perform minimally invasive procedures in digestive, thoracic, urology, and gynecology areas. Researchers will track complications, tech…

This study looks at whether giving a lower dose of immunotherapy (pembrolizumab or nivolumab) causes fewer serious side effects than the standard higher dose. About 192 adults with solid tumors will be randomly assigned to receive either the higher or lower dose. The main goal is…

This study will compare levels of fatty acid binding proteins and cellular aging markers in 120 cancer survivors versus people who never had cancer. Researchers want to see if these markers are higher in survivors and linked to conditions like diabetes and high blood pressure. Pa…

This study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…

This study asks 3000 teens and young adults (ages 15-39) with cancer, along with their caregivers, to answer survey questions about body image, fertility, and financial stress. The goal is to create better tools to measure quality of life for future patients. Participants include…

This study follows 6,000 adults with solid tumors who are receiving immune checkpoint inhibitors as part of their routine cancer care. Researchers are tracking how long patients live and how long their disease stays under control. The goal is to learn how well these drugs work in…

This registry collects detailed information from cancer patients treated with proton radiation therapy. Researchers will track treatment plans, side effects, and quality of life over 15 years. The goal is to learn which patients benefit most from this precise form of radiation an…

This study tests a Clinical Trials Navigator program that helps cancer patients, families, and doctors find and enroll in clinical trials outside their local cancer centre. The program will be rolled out to 20 centres across Canada, starting with Thunder Bay and Winnipeg. Researc…

This study looks at genetic and behavioral factors that might influence cancer development and outcomes. It involves people with a personal or family history of cancer, who provide samples like blood, saliva, or urine. The goal is to better understand inherited cancer risks and f…

This observational study will survey 1,000 cancer patients about their use of dietary supplements like vitamins, minerals, and herbal products. Researchers want to know how common supplement use is, whether patients experience side effects, and if these supplements could interact…

This observational study is looking at whether certain markers in the blood can predict immune-related side effects in cancer patients receiving immunotherapy. Researchers will collect blood samples and health data from 200 participants during routine visits. The goal is to bette…

This study is translating and testing an Italian version of a questionnaire that measures anxiety in cancer patients during whole-body MRI scans. Researchers will enroll 175 adult cancer patients at the European Institute of Oncology. The goal is to ensure the Italian version is …

SPECTA is a large research platform that collects tumor samples, genetic data, and patient information from nearly 5,000 people with all types of cancer. The goal is to help scientists better understand cancer biology and find new ways to match patients with the right clinical tr…

This study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…

This study is testing whether people in early-phase cancer trials will consistently wear a smartwatch and complete weekly symptom surveys on a phone app. Thirty participants will use the devices for 4 weeks. The goal is to see if this approach is practical and acceptable, not to …

This Mayo Clinic study is collecting blood samples from 30 cancer patients to create personalized stem cell models. The goal is to understand why some people have severe side effects from cancer therapy while others do not. This is a non-interventional study, meaning no new treat…

This early-stage study looks at how the experimental drug saruparib is absorbed, distributed, and eliminated in 8 people with advanced solid tumors. Participants will receive the drug by mouth and by vein, with samples taken to track the drug and its breakdown products. The goal …

This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…

This study is collecting data from 2,000 adults with solid tumors who undergo theranostic PET scans as part of their routine care. The goal is to see how well these scans detect tumors and match with lab results, which could help doctors make better treatment decisions. Participa…

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …

This study follows 334 cancer patients to see if switching between different-looking generic chemo pills affects their adherence and health outcomes. Researchers will track pill counts and patient surveys over six months. The goal is to understand if changes in pill color, shape,…

This study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…

This study tests a program called SUPPORT that helps Black and Latino cancer patients learn about and join clinical trials. The program includes a website and a navigator who guides patients. Researchers will see if this increases the number of patients referred to and enrolled i…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study from Mayo Clinic is looking at how T cells (a type of immune cell) change during anti-PD-1 immunotherapy in people with advanced melanoma, lung cancer, or other solid tumors. Researchers will collect blood and tissue samples from 500 participants to measure specific ma…

This study looks at liver inflammation (hepatitis) that can occur in cancer patients treated with immune checkpoint inhibitors, a type of immunotherapy. Researchers aim to describe the different patterns of liver injury and how they respond to treatment. By collecting real-world …

This study will follow 1 million Chinese adults with cancer to measure how common and severe cancer-related fatigue is. Researchers will look at what factors influence fatigue and how it affects treatment and survival. The goal is to better understand this common but often overlo…

This study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This study is collecting blood and urine samples from 150 cancer patients who have had blood clots. The goal is to learn more about why clots happen in cancer and how to prevent them. Participants will be followed over time to track clot recurrence and bleeding risks.

This study is collecting information on side effects from proton therapy in 5,000 adults with many types of cancer. Researchers will track both short-term and long-term side effects and link them to the details of each patient's treatment plan. The goal is to better predict who m…

This study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This study is testing a program to help Native American cancer patients get better coordinated care. It brings together a cancer center and tribal health systems to improve communication and support. About 187 adults newly diagnosed with cancer will take part. The goal is to see …

This study screens adults with certain cancers (like melanoma, lung, or colorectal cancer) to see if they qualify for experimental treatments being tested by the NCI Surgery Branch. These treatments involve taking a patient's own immune cells, growing them in a lab, and giving th…

This study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…

This study collects tumor tissue, blood, and cheek swabs from 50 adults with cancer to create personalized 3D models in the lab. Researchers will analyze the genetics and drug responses of these models to find new treatment targets. The goal is to improve understanding of aggress…

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study collects blood or apheresis samples from 24 people with solid tumors and healthy volunteers. Researchers will analyze immune cells to see how they respond to a neoantigen vaccine, which is designed to help the immune system recognize cancer. The goal is to learn how to…

This study will follow 6,000 children, adolescents, and young adults with cancer in low- and middle-income countries. Researchers will collect data from medical records and questionnaires to understand why treatment failure and severe side effects are more common in these setting…

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

This early-phase study tests a new radioactive tracer called [89Zr]DFO-starPEG to see if it can make tumors show up better on PET scans. The goal is to learn how the tracer behaves in the body and whether it can help doctors see the "leakiness" of tumor blood vessels, which may g…

This study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…

This study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…

This study follows 600 childhood cancer survivors aged 8-18 to understand why symptoms like fatigue, pain, and depression often occur together. Researchers will use questionnaires and stool samples to see if gut bacteria and their byproducts play a role. The goal is to find bette…

This study tests a new communication tool called 'Let's Get REAL' that helps children and teens (ages 8-17) and their families talk together about stem cell transplant or cellular therapy decisions. The goal is to see if the tool is easy to use and helpful for families. About 60 …

This study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …

This observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…

This study uses a special microscope called intravital microscopy to look at blood vessels inside solid tumors while patients are in surgery. Researchers want to see how these vessels work and how well they let blood and dye flow through. The goal is to learn whether tumor vessel…

This study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…

This study looks at 200 adults with moderate to severe cancer pain who are taking opioid painkillers like hydrocodone or oxycodone. Researchers will use smartwatches and questionnaires to track pain, sleep quality, and mood over three months. The goal is to understand how pain, i…

This study is collecting medical data and tumor or blood samples from 500 adults with malignant tumors treated at a Chinese hospital between 2017 and 2025. Researchers will analyze genes, immune cells, and other molecular features to understand what affects survival and treatment…

This study looks at how the COVID-19 pandemic impacted the emotional, financial, physical, and social well-being of adolescent and young adult (AYA) cancer patients and survivors. Researchers will survey 600 participants to measure COVID-related distress and changes in health beh…

This study enrolls adults with cancer or benign tumors who are already participating in other trials at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a patient's past, current, and future studies. The goal is to …

This study aims to build a large biobank of blood samples from 40,000 cancer patients to help identify biomarkers that can predict survival and response to treatment. Participants provide an extra 36ml of blood during routine blood draws. The samples will be used in future resear…

This study explores the link between physical activity and thinking skills in people who survived cancer as adolescents or young adults. Researchers will use computer-based brain games to measure memory and attention. The goal is to understand how exercise might help brain health…

This study asks 300 adolescents and young adults (ages 15-39) who have or had cancer to fill out questionnaires. The goal is to find gaps in education about exercise, sexual health, fertility, finances, and more. No treatment is given—just a survey to help improve future care.

This study follows families with a history of inherited kidney cancer to learn more about the disease's genetic causes and how it progresses. Researchers will collect blood, tissue, and urine samples from affected individuals and their relatives. The goal is to identify new genes…

This study is testing a new questionnaire called PRO-AYA, designed to measure quality of life in adolescents and young adults (ages 15-39) with cancer. Researchers want to see if the survey is reliable and accurate, including a Spanish version. 120 participants will fill out the …

This study looks at how gut bacteria affect immunotherapy in people with advanced solid tumors. It has two parts: first, finding bacterial markers linked to treatment response; second, testing if fecal transplants from healthy donors can make immunotherapy work better. About 60 a…

This study, led by Mayo Clinic, will take leftover tumor tissue from 250 cancer patients after surgery. Researchers will treat small fragments of the live tumor with different chemotherapy and immunotherapy drugs in the lab, monitoring responses over 72 hours. The goal is to see …

This study works with cancer survivors and their loved ones living in poor areas to improve their diet and physical activity. Researchers will adapt existing health programs to fit the community's needs. About 100 participants from the Birmingham area will track their eating, exe…

This study looks at the reasons parents consider when deciding whether to enroll their child in a cancer clinical trial. Researchers will survey and interview 400 parents of children newly diagnosed with cancer. The goal is to understand how social factors, personal preferences, …

This study is testing a new safety tool for cancer patients on chemotherapy. Patients wear a wristband with a QR code. If they go to the emergency room, doctors can scan the code and quickly fill out a checklist about possible serious side effects. The goal is to see if this help…

This study uses anonymous surveys to ask cancer patients, healthcare professionals, and industry workers whether the UK's 1939 Cancer Act—which bans advertising cancer treatments to the public—still works in today's digital world. The goal is to understand how people use online a…

This study is developing and testing a program to help female adolescent and young adult cancer survivors make informed decisions about building a family after treatment. The program includes four video sessions that provide personalized education about fertility risks and coping…

This study analyzes the DNA of solid tumors from 5,500 cancer patients to find genetic changes that could be targeted by specific treatments. The goal is to use this molecular profile to match patients with appropriate clinical trials. Participants must have a confirmed solid tum…

This study is for people with advanced solid tumors who have run out of standard treatment options. Researchers will track how well off-label or non-standard therapies work when chosen based on the tumor's genetic profile. The goal is to create a standard way to measure responses…

This study follows 1,538 cancer patients in China to see how their nutritional status affects how well they handle chemotherapy and radiation, their quality of life, and how long they live. Researchers will track changes in diet, weight, and blood markers over time. The goal is t…

This study enrolls 7,000 people with various cancers who have had or will have treatment aimed at a cure. Researchers collect blood, tissue, urine, and saliva samples over time to look for tiny bits of cancer DNA left behind. The goal is to find any remaining cancer as early as p…

This study is building a registry of 500 children, teens, and young adults (ages 1-39) diagnosed with cancer. Participants will complete physical and mental function tests, surveys, and provide blood samples over time. The goal is to learn how cancer and its treatments affect agi…

This study is developing and testing a patient navigation program designed specifically for American Indian and Alaska Native cancer patients in rural California. The program helps patients overcome barriers like distance, mistrust, and complex healthcare systems. Researchers wil…

This study is testing whether a website with a virtual community health educator can help Black and Hispanic cancer patients in Florida learn about and sign up for clinical trials. About 350 adults will be randomly assigned to either a standard information portal or one with a vi…

This study looks at two ways to place a thin, flexible tube (called a PICC) in cancer patients who need long-term IV treatments. One method uses magnetic tracking, and the other uses heart signals (ECG) to guide the tube to the right spot. Researchers want to see which method wor…

This study tests a high-resolution PET-CT scanner that images removed tumors right in the operating room. About 50 adults with solid cancers will get a standard PET tracer before surgery, then the removed tissue is scanned to see if all cancer was taken out. The goal is to see if…

This study looks at how tumors and nearby healthy organs change in size and shape during and after radiation therapy. Researchers will measure these changes in 500 people who have already completed radiation treatment. The goal is to learn more about these changes so doctors can …

This study looks at whether giving doctors genetic information about their patients can help them choose safer and more effective pain medications. Researchers will enroll 800 cancer patients who are expected to need opioid painkillers. Half will have their genes tested to guide …